Abstract:The AT‐rich interacting domain‐containing protein 1A (ARID1A) is a tumor suppressor gene that has been implicated in several cancers, including colorectal cancer (CRC). The present study used a proteomic approach to elucidate the molecular mechanisms of ARID1A in CRC carcinogenesis. Stable ARID1A‐overexpressing SW48 colon cancer cells were established using lentivirus transduction and the successful overexpression of ARID1A was confirmed by western blotting. Label‐free quantitative proteomic analysis using liquid chromatography‐tandem mass spectrometry identified 705 differentially altered proteins in the ARID1A‐overexpressing cells, with 310 proteins significantly increased and 395 significantly decreased compared with empty vector control cells. Gene Ontology enrichment analysis highlighted the involvement of the altered proteins mainly in the Wnt signaling pathway. Western blotting supported these findings, as a decreased protein expression of Wnt target genes, including c‐Myc, transcription factor T cell factor‐1/7 and cyclin D1, were observed in ARID1A‐overexpressing cells. Among the altered proteins involved in the Wnt signaling pathway, the interaction network analysis revealed that ARID1A exhibited a direct interaction with E3 ubiquitin‐protein ligase zinc and ring finger 3 (ZNRF3), a negative regulator of the Wnt signaling pathway. Further analyses using the The Cancer Genome Atlas colon adenocarcinoma public dataset revealed that ZNRF3 expression significantly impacted the overall survival of patients with CRC and was positively correlated with ARID1A expression. Finally, an increased level of ZNRF3 in ARID1A‐overexpressing cells was confirmed by western blotting. In conclusion, the findings of the present study suggest that ARID1A negatively regulates the Wnt signaling pathway through ZNRF3, which may contribute to CRC carcinogenesis.

Research Progress of the Tumor Suppressor ARID1A

Tumor suppressor role of chromatin-remodeling factor ARID1A]

Advances in research on ARID1 A in Malignancies

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

ARID1A is Downregulated in Non-Small Cell Lung Cancer and Regulates Cell Proliferation and Apoptosis

ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response

ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications.

Deciphering the regulatory mechanisms and biological implications of ARID1A missense mutations in cancer

ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines

Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer

ARID1A Deficiency Weakens BRG1-RAD21 Interaction That Jeopardizes Chromatin Compactness and Drives Liver Cancer Cell Metastasis.

ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner

ARID1A regulates R-loop associated DNA replication stress

Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors

Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response

ARID1A in Gynecologic Precancers and Cancers

Proteomic insights into the regulatory function of ARID1A in colon cancer cells

Increased genomic instability and reshaping of tissue microenvironment underlie oncogenic properties of Arid1a mutations

ARID1A and CEBPα cooperatively inhibit UCA1 transcription in breast cancer

Therapeutic targeting of ARID1A-deficient cancer cells with RITA (Reactivating p53 and inducing tumor apoptosis)

Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency